Skip to main content

Table 1 Distributions of potential risk factors for occurrence of cardiovascular events in RA patients at baseline

From: Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature

 

N = 480

Demographics

 

Sex (n,% female)

347 (72.3)

Age (mean, SD)

59.0 (13.0)

Traditional CV risk factors

 

Smoking, current (n,%)

114 (23.8)

Systolic blood pressure (mmHg, mean, SD)

144.0 (22.9)

Total cholesterol (mmol/L, SD)

5.3 (0.99)

LDL cholesterol (mmol/L, SD)

3.1 (0.83)

Triglycerides (mmol/L, SD)

1.3 (0.65)

Atherogenic index (mean, SD)

3.7 (1.1)

GlyHb (%, mean, SD)

5.8 (0.67)

SCORE 10-year estimated CV risk (%, SD))

5.7 (4.9)

Inflammatory markers

 

ESR (mm/hr, mean, SD)

16.5 (14.9)

Hs CRP (mg/L, mean, SD)

7.0 (10.0)

RA disease characteristics

 

RA disease duration (years; median, 25th-75th percentile)

4.2 (1.5-11.3)

Seropositive (anti-CCP and/or IgMRF; n,%)

286 (63.3)

Erosions (n,%)

198 (42.2)

DAS 28 (mean, SD)

2.5 (1.2)

Remission (n,%)

223 (72.1)

Medication

 

DMARD (n,%)

350 (72.9)

MTX (n,%)

291 (60.6)

TNFα inhibitor (n,%)

105 (21.9)

NSAID (n,%)

177 (36.9)

Corticosteroids (n,%)

68 (14.2)

  1. (RA: rheumatoid arthritis; CV: cardiovascular; SD: standard deviation; LDL: low density lipoprotein; GlyHb: glycated hemoglobin; ESR: erythrocyte sedimentation rate; Hs CRP: high sensitivity C-reactive protein; anti CCP: anti cyclic citrullinated protein; IgM RF: IgM rheumatoid factor; DAS28: disease activity score in 28 joints; DMARD: disease modifying antirheumatic drug; MTX: methotrexate; TNF inhibitor: tumour necrosis factor α inhibitor; NSAID: non steroidal anti inflammatory drug).